Emerging Vaccine-Breakthrough SARS-CoV-2 Variants.

Area of Science:

• Virology
• Genomics
• Immunology

Background:

• The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants like Alpha, Beta, Gamma, and Delta has accelerated COVID-19 spread.
• Over 28,000 unique mutations, including over 4,000 on the spike protein, complicate understanding viral evolution and vaccine efficacy.
• Comprehending SARS-CoV-2 evolution is crucial for predicting vaccine-breakthrough variants and designing universal vaccines and therapeutics.

Purpose of the Study:

• To elucidate the molecular mechanisms behind SARS-CoV-2 evolution and variant emergence.
• To forecast the emergence of vaccine-breakthrough variants.
• To identify potential targets for mutation-proof vaccines and monoclonal antibodies.

Main Methods:

• Genomic analysis of over 1.4 million SARS-CoV-2 genomes.
• Integration of antibody library data, mutational data, topological data analysis, and deep learning.
• Analysis of evolutionary pressures, including natural selection and vaccination-induced responses.

Main Results:

• Viral evolution is primarily driven by mutations that enhance infectivity, with vaccine escape becoming dominant in highly vaccinated populations.
• The Lambda variant exhibits infectivity comparable to Delta but with increased vaccine resistance.
• Specific mutation combinations, such as [A411S, L452R, T478K] and [L452R, T478K, E484K, N501Y], were identified as likely to confer significant growth and vaccine escape.

Conclusions:

• Infectivity-enhancing mutations are key drivers of SARS-CoV-2 evolution.
• Vaccine-escape mutations are increasingly dominant, posing a threat to existing vaccines.
• Urgent development of novel antiviral strategies is required to combat emerging and potentially vaccine-evading SARS-CoV-2 variants.